Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3335-3340

  Yoshiji, Hitoshi ^a   Noguchi, Ryuichi ^a   Kuriyama, Shigeki ^b   Yoshii, Junichi ^a   Ikenaka, Yasuhide ^a   Yanase, Koji ^a   Namisaki, Tadashi ^a   Kitade, Mitsuteru ^a   Yamazaki, Masaharu ^a   Uemura, Masahito ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

ACE inhibitor; Angiogenesis; Hepatocarcinogenesis; Renin angiotensin system

Indexed keywords

ALANINE AMINOTRANSFERASE; ANGIOGENIC FACTOR; ANGIOTENSIN; CD31 ANTIGEN; DIETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE; MESSENGER RNA; PERINDOPRIL; RENIN; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; MALE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARCINOGENS; CELL GROWTH PROCESSES; DIETHYLNITROSAMINE; ENDOTHELIAL CELLS; GLUTATHIONE TRANSFERASE; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; NEOVASCULARIZATION, PATHOLOGIC; PERINDOPRIL; PRECANCEROUS CONDITIONS; RATS; RATS, INBRED F344; RENIN-ANGIOTENSIN SYSTEM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 23344446945     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
2. Carmeliet P: Angiogenesis in health and disease. Nat Med 9: 653-660, 2003.
3. Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, Lin P and Dewhirst MW: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92: 143-147, 2000.
4. Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410, 2003.
5. Bergers G, Javaherian K, Lo KM, Folkman J and Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812, 1999.
6. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z and Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2: 737-744, 2000.
7. Harris SR and Thorgeirsson UP: Tumor angiogenesis: biology and therapeutic prospects. In Vivo 12: 563-570, 1998.
8. Fox SB, Gatter KC and Harris AL: Tumour angiogenesis. J Pathol 779: 232-237, 1996.
9. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
10. Shibuya M: Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26: 25-35, 2001.
11. Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ and Ellis LM: Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89: 488-499, 2000.
12. Befeler AS and Di Bisceglie AM: Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 722: 1609-1619, 2002.
13. Schafer DF and Sorrell MF: Hepatocellular carcinoma. Lancet 353: 1253-1257, 1999.
14. Chow N H, Hsu PI, Lin XZ, Yang HB, Chan SH, Cheng KS, Huang SM and Su IJ: Expression of vascular endothelial growth factor in normal liver and hepatocellular carcinoma: an immunohistochemical study. Hum Pathol 28: 698-703, 1997.
15. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M, Fujita J and Imamura M: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23: 455-464, 1996.
16. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y and Ohnishi S: Increased expression of vascular endothelial growth factor in human hepatocellular carcinoma. J Hepatol 27: 854-861, 1997.
17. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K and Kamada T: Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 56: 3004-3009, 1996.
18. Yamaguchi R, Yano H, Nakashima Y, Ogasawara S, Higaki K, Akiba J, Hicklin DJ and Kojiro M: Expression and localization of vascular endothelial growth factor receptors in human hepatocellular carcinoma and non-HCC tissues. Oncol Rep 7: 725-729, 2000.
19. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M and Kojiro M: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68-77,1998.
20. Yoshiji H, Kuriyama S, Yoshii J, Yamazaki M, Kikukawa M, Tsujinoue H, Nakatani T and Fukui H: Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 28: 1489-1496, 1998.
21. Park YN, Kim YB, Yang KM and Park C: Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis. Arch Pathol Lab Med 124: 1061-1065, 2000.
22. Frachon S, Gouysse G, Dumorti J, Couvelard A, Nejjari M, Mion F, Berger F, Paliard P, Boillot O and Scoazec JY: Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol 34: 850-857, 2001.
23. Kin M, Torimura T, Ueno T, Nakamura T, Ogata R, Sakamoto M, Tamaki S and Sata M: Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 16: 375-382, 2000.
24. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T and Fukui H: Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice. Hepatology 39: 1517-1524, 2004.
25. Matsusaka T and Ichikawa I: Biological functions of angiotensin and its receptors. Annu Rev Physiol 59: 395-412, 1997.
26. Yoshiji H, Kuriyama S and Fukui H: Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 23: 348-356, 2002.
27. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T, Imazu H, Yanase K, Kuriyama S and Fukui H: Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 37: 22-30, 2002.
28. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H and Fukui H: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7: 1073-1078, 2001.
29. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H and Fukui H: Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34: 745-750, 2001.
30. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Huber J, Nakatani T, Tsujinoue H, Yanase K, Imazu H and Fukui H: Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35: 834-842, 2002.
31. Okita K, Sakaida I and Hino K: Current strategies for chemoprevention of hepatocellular carcinoma. Oncology 62(Suppl 1): 24-28, 2002.
32. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and Robertson JW: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352: 179-184, 1998.
33. Noguchi R, Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Mitoro A, Tsujinoue H, Imazu H, Masaki T and Fukui H: Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 9: 6038-6045, 2003.
34. Monton M, Castilla MA, Alvarez Arroyo MV, Tan D, Gonzalez-Pacheco FR, Lopez Farre A, Casado S and Caramelo C: Effects of angiotensin II on endothelial cell growth: role of AT-1 and AT-2 receptors. J Am Soc Nephrol 9: 969-974, 1998.
35. Yoshiji H, Kuriyama S and Fukui H: Perindopril: possible use in cancer therapy. Anticancer Drugs 13: 221-228, 2002.
36. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H, Imazu H and Fukui H: Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol 20: 1227-1231, 2002.
37. Gerber HP and Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65: 671-680, 2005.
38. Thiollet M, Funck-Brentano C, Grange JD, Midavaine M, Resplandy G and Jaillon P: The pharmacokinetics of perindopril in patients with liver cirrhosis. Br J Clin Pharmacol 33: 326-328, 1992.